首页|期刊导航|医药导报|基于实验设计的报告基因法检测甘精胰岛素生物活性方法的建立及验证

基于实验设计的报告基因法检测甘精胰岛素生物活性方法的建立及验证OA

Establishment and Validation of a Reporter Gene Assay for Determining the Biological Activity of Insulin Glargine Based on Design of Experiments

中文摘要英文摘要

目的 建立基于实验设计(DOE)理念优化的报告基因法用于甘精胰岛素生物活性测定,并进行全面方法学验证.方法 利用稳定转染胰岛素受体基因、STAT5b 响应元件和荧光素酶报告基因的 HEK293 细胞(HEK293/IRL-Luc),通过响应曲面设计优化关键参数(细胞密度、药物稀释倍数、药物作用时间);依据 ICH Q2(R2)和《中华人民共和国药典》2020 年版通则进行专属性、精密度、准确度、线性及重复性验证.结果 最佳实验条件为:细胞密度每毫升(1.4~4.6)×105个、药物作用时间16 h、药物采用 2 倍系列稀释(起始浓度600 nmol•L-1).方法学验证结果表明,该生物活性测定方法专属性良好;重复性几何变异系数(GCV)≤10%,中间精密度 GCV<12%;相对偏倚及置信区间的绝对值均不超过 12%(64%~156%效价水平范围);线性范围的相关系数 R2 = 0.9908.结论 该研究建立的基于 DOE 优化的报告基因法操作简便、结果准确,可提升检测通量和可重复性,与小鼠血糖法具有良好的一致性,为重组人胰岛素质量控制提供了符合"3R"原则的体外替代方法.

Objective To establish and validate a reporter gene assay based on design of experiments(DOE)princi-ples for measuring the biological activity of insulin glargine.Methods Using HEK293 cells(HEK293/IRL-Luc)stably trans-fected with the insulin receptor gene,STAT5b response element,and luciferase reporter gene.Key assay parameters(cell densi-ty,drug dilution factor,and drug incubation time)were optimized via response surface methodology.The method was validated in accordance with ICH Q2(R2)and the General Chapters of the Chinese Pharmacopoeia(2020 Edition),assessing specificity,precision,accuracy,linearity and repeatability.Results The optimized assay conditions were as follows:cell density ranging from 1.4×105 to 4.6×105 cells per mL,drug incubation time of 16 hours,and two-fold serial dilutions of the drug starting from an initial concentration of 600 nmol•L-1.Validation results demonstrated high specificity;precision with repeatability(GCV≤10%)and intermediate precision(GCV<12%);accuracy with relative bias and its confidence intervals within±12%across the potency range of 64%-156%;and excellent linearity(R2=0.9908).Conclusions The reporter gene assay optimized based on DOE and established in this study features straightforward operation and accurate results,enhances detection throughput and reproducibility,and demonstrates strong consistency with the mouse blood glucose method.It provides an in vitro alternative ap-proach compliant with the"3R"principles for the quality control of recombinant human insulin products.

徐小玲;史梦婷;徐巾晶;马利;吕晓君;何开勇

湖北省药品监督检验研究院,武汉 430064湖北省药品监督检验研究院,武汉 430064湖北省药品监督检验研究院,武汉 430064宜昌东阳光长江药业胰岛素工厂,宜昌 443000湖北省药品监督检验研究院,武汉 430064湖北省药品监督管理局药品审评检查中心,武汉 430070

医药卫生

甘精胰岛素生物活性报告基因法

Insalin glargineBiological activityReporter gene assay

《医药导报》 2026 (4)

699-705,7

湖北省技术创新计划资助项目(2023BCB097).

10.3870/j.issn.1004-0781.2026.04.020

评论